Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 9, 2016, Pages 2232-2239

  Elster, Jennifer D ^a   Krishnadas, Deepa K ^a   Lucas, Kenneth G ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

cancer immunotherapy; dendritic cell; dendritic cell vaccine; vaccine adjuvant

Indexed keywords

DECITABINE; DENDRITIC CELL VACCINE; TUMOR ANTIGEN; CANCER VACCINE;

CANCER IMMUNOTHERAPY; CANCER STEM CELL; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LEUKAPHERESIS; NEUROBLASTOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHLEBOTOMY; REVIEW; SURVIVAL RATE; BIOLOGICAL THERAPY; CHILD; DENDRITIC CELL; IMMUNOLOGY; NEOPLASMS; PROCEDURES;

CANCER VACCINES; CELL- AND TISSUE-BASED THERAPY; CHILD; DENDRITIC CELLS; HUMANS; NEOPLASMS;

EID: 84987819652     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1179844     Document Type: Review

References (75)

1. E.Ward, C.DeSantis, A.Robbins, B.Kohler, A.Jemal. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64:83-103; PMID:24488779
2. D.A.Mitchell, E.J.Sayour, E.Reap, R.Schmittling, G.DeLeon, P.Norberg, A.Desjardins, A.H.Friedman, H.S.Friedman, G.Archer, et al. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol research 2015; 3:320-5; PMID:25387895; http://dx.doi.org/10.1158/2326-6066.CIR-14-0100
3. D.K.Krishnadas, S.Shusterman, F.Bai, L.Diller, J.E.Sullivan, A.C.Cheerva, R.E.George, K.G.Lucas. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother 2015; 64:1251-60; PMID:26105625; http://dx.doi.org/10.1007/s00262-015-1731-3
4. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
5. H.Ardon, S.De Vleeschouwer, F.Van Calenbergh, L.Claes, C.M.Kramm, S.Rutkowski, J.E.Wolff, S.W.Van Gool. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediat Blood Cancer 2010; 54:519-25; PMID:19852061
6. D.A.Caruso, L.M.Orme, A.M.Neale, F.J.Radcliff, G.M.Amor, W.Maixner, P.Downie, T.E.Hassall, M.L.Tang, D.M.Ashley. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncology 2004; 6:236-46; PMID:15279716; http://dx.doi.org/10.1215/S1152851703000668
7. J.L.Lasky, 3rd, E.H.Panosyan, A.Plant, T.Davidson, W.H.Yong, R.M.Prins, L.M.Liau, T.B.Moore. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013; 33:2047-56; PMID:23645755
8. A.M.Dohnal, V.Witt, H.Hugel, W.Holter, H.Gadner, T.Felzmann. Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 2007; 9:755-70; PMID:17917887; http://dx.doi.org/10.1080/14653240701589221
9. J.Geiger, R.Hutchinson, L.Hohenkirk, E.McKenna, A.Chang, J.Mule. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet (London, England) 2000; 356:1163-5; PMID:11030299; http://dx.doi.org/10.1016/S0140-6736(00)02762-8
10. J.D.Geiger, R.J.Hutchinson, L.F.Hohenkirk, E.A.McKenna, G.A.Yanik, J.E.Levine, A.E.Chang, T.M.Braun, J.J.Mule. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61:8513-9; PMID:11731436
11. N.Himoudi, R.Wallace, K.L.Parsley, K.Gilmour, A.U.Barrie, K.Howe, R.Dong, N.J.Sebire, A.Michalski, A.J.Thrasher, et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol 2012; 14:271-9; PMID:22484634; http://dx.doi.org/10.1007/s12094-012-0795-1
12. A.Matsuzaki, A.Suminoe, H.Hattori, T.Hoshina, T.Hara. Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma. J Pediat Hematol Oncol 2002; 24:220-3; PMID:11990310; http://dx.doi.org/10.1097/00043426-200203000-00012
13. J.Shilyansky, P.Jacobs, K.Doffek, S.L.Sugg. Induction of cytolytic T lymphocytes against pediatric solid tumors in vitro using autologous dendritic cells pulsed with necrotic primary tumor. J Pediat Surgery 2007; 42:54-61; discussion; PMID:17208541; http://dx.doi.org/10.1016/j.jpedsurg.2006.09.008
14. A.Suminoe, A.Matsuzaki, H.Hattori, Y.Koga, T.Hara. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors. Pediat Transplant 2009; 13:746-53; PMID:19067917; http://dx.doi.org/10.1111/j.1399-3046.2008.01066.x
15. M.K.Hunn, E.Bauer, C.E.Wood, O.Gasser, M.Dzhelali, L.R.Ancelet, B.Mester, K.J.Sharples, M.P.Findlay, D.A.Hamilton, et al. Dendritic cell vaccination combined with temozolomide retreatment:results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neuro-Oncol 2015; 121:319-29; PMID:25366363; http://dx.doi.org/10.1007/s11060-014-1635-7
16. S.Saito, R.Yanagisawa, K.Yoshikawa, Y.Higuchi, T.Koya, K.Yoshizawa, M.Tanaka, K.Sakashita, T.Kobayashi, T.Kurata, et al. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia:a case report and review of the literature. Cytotherapy 2015; 17:330-5; PMID:25484308; http://dx.doi.org/10.1016/j.jcyt.2014.10.003
17. S.K.Nair, T.Driscoll, D.Boczkowski, R.Schmittling, R.Reynolds, L.A.Johnson, G.Grant, H.Fuchs, D.D.Bigner, J.H.Sampson, et al. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. J Neuro-oncol 2015; 125:65-74; PMID:26311248; http://dx.doi.org/10.1007/s11060-015-1890-2
18. J.F.Jacobs, P.M.Hoogerbrugge, M.W.de Rakt, E.H.Aarntzen, C.G.Figdor, G.J.Adema, I.J.de Vries. Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediat Blood Cancer 2007; 49:924-7; PMID:17486645; http://dx.doi.org/10.1002/pbc.21246
19. J.Vakkila, K.Vettenranta, H.Sariola, U.M.Saarinen-Pihkala. Poor yield of dendritic cell precursors from untreated pediatric cancer. J Hematother Stem Cell Res 2001; 10:787-93; PMID:11798505; http://dx.doi.org/10.1089/152581601317210881
20. M.Haruta, Y.Tomita, A.Yuno, K.Matsumura, T.Ikeda, K.Takamatsu, E.Haga, C.Koba, Y.Nishimura, S.Senju. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther 2013; 20:504-13; PMID:22875043; http://dx.doi.org/10.1038/gt.2012.59
21. S.Lonial, M.Hicks, H.Rosenthal, A.Langston, I.Redei, C.Torre, M.Duenzl, B.Feinstein, J.Cherry, E.K.Waller. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004; 10:848-57; PMID:15570253; http://dx.doi.org/10.1016/j.bbmt.2004.07.008
22. M.Arpinati, C.L.Green, S.Heimfeld, J.E.Heuser, C.Anasetti. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95:2484-90; PMID:10753825
23. J.Zeng, C.Wu, S.Wang. Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells. Sci Rep 2015; 5:15262; PMID:26471005; http://dx.doi.org/10.1038/srep15262
24. H.Iwamoto, T.Ojima, M.Nakamori, M.Nakamura, K.Hayata, M.Katsuda, T.Iida, M.Miyazawa, M.Iwahashi, H.Yamaue. [Cancer vaccine therapy using genetically modified induced pluripotent stem cell-derived dendritic cells expressing the TAA gene]. Gan To kagaku Ryoho Cancer Chemother 2013; 40:1575-7; PMID:24393853
25. S.Fukushima, S.Hirata, Y.Motomura, D.Fukuma, Y.Matsunaga, Y.Ikuta, T.Ikeda, T.Kageshita, H.Ihn, Y.Nishimura, et al. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother 2009; 32:219-31; PMID:19242378; http://dx.doi.org/10.1097/CJI.0b013e318194b63b
26. J.Zeng, S.Wang. Human dendritic cells derived from embryonic stem cells stably modified with CD1d efficiently stimulate antitumor invariant natural killer T cell response. Stem Cell Transl Med 2014; 3:69-80; PMID:24292792; http://dx.doi.org/10.5966/sctm.2013-0070
27. C.de Haar, M.Plantinga, N.J.Blokland, N.P.van Til, T.W.Flinsenberg, V.F.Van Tendeloo, E.L.Smits, L.Boon, L.Spel, M.Boes, et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology 2015; 4:e1023973; PMID:26451309; http://dx.doi.org/10.1080/2162402X.2015.1023973
28. K.Sakai, S.Shimodaira, S.Maejima, N.Udagawa, K.Sano, Y.Higuchi, T.Koya, T.Ochiai, M.Koide, S.Uehara, et al. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015; 123:989-97; PMID:26252465; http://dx.doi.org/10.3171/2015.1.JNS141554
29. A.Collignon, A.T.Perles-Barbacaru, S.Robert, F.Silvy, E.Martinez, I.Crenon, S.Germain, S.Garcia, A.Viola, D.Lombardo, et al. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Oncotarget 2015; 6:23462-79; PMID:26405163; http://dx.doi.org/10.18632/oncotarget.4359
30. M.Okamoto, M.Kobayashi, Y.Yonemitsu, S.Koido, S.Homma. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther 2016; 7:133-8; PMID:26855819; http://dx.doi.org/10.4292/wjgpt.v7.i1.133
31. S.T.Nguyen, H.L.Nguyen, V.Q.Pham, G.T.Nguyen, C.D.Tran, N.K.Phan, P.V.Pham. Targeting specificity of dendritic cells on breast cancer stem cells:in vitro and in vivo evaluations. Onco Targets Ther 2015; 8:323-34; PMID:25674007
32. X.Wang, M.E.Bayer, X.Chen, C.Fredrickson, A.N.Cornforth, G.Liang, J.Cannon, J.He, Q.Fu, J.Liu, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015; 111:862-7; PMID:25873455; http://dx.doi.org/10.1002/jso.23897
33. E.O.Vik-Mo, M.Nyakas, B.V.Mikkelsen, M.C.Moe, P.Due-Tonnesen, E.M.Suso, S.Saeboe-Larssen, C.Sandberg, J.E.Brinchmann, E.Helseth, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; http://dx.doi.org/10.1007/s00262-013-1453-3
34. S.Wilgenhof, J.Corthals, A.M.Van Nuffel, D.Benteyn, C.Heirman, A.Bonehill, K.Thielemans, B.Neyns. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 2015; 64:381-8; PMID:25548092; http://dx.doi.org/10.1007/s00262-014-1642-8
35. M.R.Olin, W.Low, D.H.McKenna, S.J.Haines, T.Dahlheimer, D.Nascene, M.P.Gustafson, A.B.Dietz, H.B.Clark, W.Chen, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer 2014; 2:4; PMID:24829761; http://dx.doi.org/10.1186/2051-1426-2-4
36. D.Kabelitz, R.Medzhitov. Innate immunity–cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr Opin Immunol 2007; 19:1-3; PMID:17157490; http://dx.doi.org/10.1016/j.coi.2006.11.018
37. C.Reis e Sousa. Toll-like receptors and dendritic cells:for whom the bug tolls. Semin Immunol 2004; 16:27-34; PMID:14751761; http://dx.doi.org/10.1016/j.smim.2003.10.004
38. H.T.B.Shen, W.E.Walker, D.R.Goldstein. Dual signaling of MyD88 and TRIF is critical for maximal TLR4-induced dendritic cell maturation. J Immunol 2008; 181:1849-58; PMID:18641322; http://dx.doi.org/10.4049/jimmunol.181.3.1849
39. G.R.A.Napolitani, F.Bertoni, F.Sallusto, A.Lanzavecchia. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunol 2005; 6:769-76; PMID:15995707; http://dx.doi.org/10.1038/ni1223
40. C.N.Baxevanis, I.F.Voutsas, O.E.Tsitsilonis. Toll-like receptor agonists:current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. Immunotherapy 2013; 5:497-511; PMID:23638745; http://dx.doi.org/10.2217/imt.13.24
41. L.Engell-Noerregaard, T.H.Hansen, M.H.Andersen, P.Thor Straten, I.M.Svane. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma:assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58:1-14; PMID:18719915; http://dx.doi.org/10.1007/s00262-008-0568-4
42. P.Sabbatini, T.Tsuji, L.Ferran, E.Ritter, C.Sedrak, K.Tuballes, A.A.Jungbluth, G.Ritter, C.Aghajanian, K.Bell-McGuinn, et al. Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients. Clin Cancer Res 2012; 18:6497-508; PMID:23032745; http://dx.doi.org/10.1158/1078-0432.CCR-12-2189
43. K.C.N.Matthews, P.J.Klasse, M.Moutaftsi, D.Carter, A.M.Salazar, S.G.Reed, R.W.Sanders, J.P.Moore. Clinical adjuvant combinations stimulate potent B-cell responses in vitro by activating dermal dendritic cells. PLoS One 2013; 8:e63785; PMID:23700434
44. I.F.J.R.Pollack, L.H.Butterfield, H.Okada. Peptide vaccine therapy for childhood gliomas. Neurosurgery 2013; 60:113-9; PMID:23839362; http://dx.doi.org/10.1227/01.neu.0000430769.33467.68
45. H.Okada, P.Kalinski, R.Ueda, A.Hoji, G.Kohanbash, T.E.Donegan, A.H.Mintz, J.A.Engh, D.L.Bartlett, C.K.Brown, et al. Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With a-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. J Clin Oncol 2011; 29:330-6; PMID:21149657; http://dx.doi.org/10.1200/JCO.2010.30.7744
46. W.T.Chang, T.H.Lai, Y.J.Chyan, S.Y.Yin, Y.H.Chen, W.C.Wei, N.S.Yang. Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis. PloS One 2015; 10:e0122374; PMID:25825910; http://dx.doi.org/10.1371/journal.pone.0122374
47. C.C.Lin, I.H.Pan, Y.R.Li, Y.G.Pan, M.K.Lin, Y.H.Lu, H.C.Wu, C.L.Chu. The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines. PloS One 2015; 10:e0116191; PMID:25723174; http://dx.doi.org/10.1371/journal.pone.0116191
48. Y.Wang, X.Ma, C.Su, B.Peng, J.Du, H.Jia, M.Luo, C.Fang, Y.Wei. Uric acid enhances the antitumor immunity of dendritic cell-based vaccine. Sci Rep 2015; 5:16427; PMID:26553557; http://dx.doi.org/10.1038/srep16427
49. A.Seth, M.B.Heo, M.H.Sung, Y.T.Lim. Infection-mimicking poly(gamma-glutamic acid) as adjuvant material for effective anti-tumor immune response. Int J Biol Macromol 2015; 75:495-504; PMID:25709015; http://dx.doi.org/10.1016/j.ijbiomac.2015.02.013
50. D.A.Mitchell, K.A.Batich, M.D.Gunn, M.N.Huang, L.Sanchez-Perez, S.K.Nair, K.L.Congdon, E.A.Reap, G.E.Archer, A.Desjardins, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015; 519:366-9; PMID:25762141; http://dx.doi.org/10.1038/nature14320
51. T.H.Kang, Y.S.Kim, S.Kim, B.Yang, J.J.Lee, H.J.Lee, J.Lee, I.D.Jung, H.D.Han, S.H.Lee, et al. Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. Oncotarget 2015; 6:27751-62; PMID:26336989; http://dx.doi.org/10.18632/oncotarget.4859
52. A.M.Van Nuffel, D.Benteyn, S.Wilgenhof, J.Corthals, C.Heirman, B.Neyns, K.Thielemans, A.Bonehill. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61:1033-43; PMID:22159452; http://dx.doi.org/10.1007/s00262-011-1176-2
53. D.Benteyn, A.M.Van Nuffel, S.Wilgenhof, A.Bonehill. Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules. Methods Mol Biol 2014; 1139:3-15; PMID:24619665; http://dx.doi.org/10.1007/978-1-4939-0345-0_1
54. T.Seya, H.Shime, Y.Takeda, M.Tatematsu, K.Takashima, M.Matsumoto. Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci 2015; 106:1659-68; PMID:26395101; http://dx.doi.org/10.1111/cas.12824
55. H.Dong, S.E.Strome, D.R.Salomao, H.Tamura, F.Hirano, D.B.Flies, P.C.Roche, J.Lu, G.Zhu, K.Tamada, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nature Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
56. H.Dong, G.Zhu, K.Tamada, L.Chen. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.org/10.1038/70932
57. T.J.Curiel, S.Wei, H.Dong, X.Alvarez, P.Cheng, P.Mottram, R.Krzysiek, K.L.Knutson, B.Daniel, M.C.Zimmermann, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med 2003; 9:562-7; PMID:12704383; http://dx.doi.org/10.1038/nm863
58. Y.Ge, H.Xi, S.Ju, X.Zhang. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett 2013; 336:253-9; PMID:23523609; http://dx.doi.org/10.1016/j.canlet.2013.03.010
59. A.B.van der Waart, H.Fredrix, R.van der Voort, N.Schaap, W.Hobo, H.Dolstra. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunol Immunother 2015; 64:645-54; PMID:25724840; http://dx.doi.org/10.1007/s00262-015-1668-6
60. S.Wang, Y.Wang, J.Liu, S.Shao, X.Li, J.Gao, H.Niu, X.Wang. Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro. Onco Targets Ther 2014; 7:1389-96; PMID:25120371; http://dx.doi.org/10.2147/OTT.S65367
61. J.Rossowska, N.Anger, J.Kicielinska, E.Pajtasz-Piasecka, A.Bielawska-Pohl, J.Wojas-Turek, D.Dus. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response. Immunobiology 2015; 220:389-98; PMID:25454807; http://dx.doi.org/10.1016/j.imbio.2014.10.009
62. V.Bronte, P.Zanovello. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005; 5:641-54; PMID:16056256; http://dx.doi.org/10.1038/nri1668
63. D.J.Chung, M.Rossi, E.Romano, J.Ghith, J.Yuan, D.H.Munn, J.W.Young. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009; 114:555-63; PMID:19465693; http://dx.doi.org/10.1182/blood-2008-11-191197
64. T.S.Johnson, D.H.Munn. Host indoleamine 2,3-dioxygenase:contribution to systemic acquired tumor tolerance. Immunol Invest 2012; 41:765-97; PMID:23017145; http://dx.doi.org/10.3109/08820139.2012.689405
65. M.D.Sharma, B.Baban, P.Chandler, D.Y.Hou, N.Singh, H.Yagita, M.Azuma, B.R.Blazar, A.L.Mellor, D.H.Munn. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911
66. Y.Narita, H.Kitamura, D.Wakita, K.Sumida, K.Masuko, S.Terada, K.Nakano, T.Nishimura. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice. J Immunol 2013; 190:812-20; PMID:23248265; http://dx.doi.org/10.4049/jimmunol.1103797
67. S.Trabanelli, M.Lecciso, V.Salvestrini, M.Cavo, D.Ocadlikova, R.M.Lemoli, A.Curti. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res 2015; 2015:253191; PMID:25815345
68. D.A.Wainwright, A.L.Chang, M.Dey, I.V.Balyasnikova, C.K.Kim, A.Tobias, Y.Cheng, J.W.Kim, J.Qiao, L.Zhang, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301; PMID:24691018; http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
69. D.B.Lowe, A.Bose, J.L.Taylor, H.Tawbi, Y.Lin, J.M.Kirkwood, W.J.Storkus. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014; 3:e27589; PMID:24734217; http://dx.doi.org/10.4161/onci.27589
70. C.M.Zwaan, C.Rizzari, F.Mechinaud, D.L.Lancaster, T.Lehrnbecher, V.H.van der Velden, B.B.Beverloo, M.L.den Boer, R.Pieters, D.Reinhardt, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia:results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 2013; 31:2460-8; PMID:23715577; http://dx.doi.org/10.1200/JCO.2012.46.8280
71. K.Kobayashi, N.Miyagawa, K.Mitsui, M.Matsuoka, Y.Kojima, H.Takahashi, K.Ootsubo, J.Nagai, H.Ueno, T.Ishibashi, et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediat Blood Cancer 2015; 62:1058-60; PMID:25400122; http://dx.doi.org/10.1002/pbc.25327
72. K.H.Wu, H.P.Wu, T.Weng, C.T.Peng, Y.H.Chao. Dasatinib for a child with Philadelphia chromosome-positive acute lymphoblastic leukemia and persistently elevated minimal residual disease during imatinib therapy. Curr Oncol 2015; 22:303-6; PMID:26300669; http://dx.doi.org/10.3747/co.22.2719
73. M.S.Merchant, M.Wright, K.Baird, L.H.Wexler, C.Rodriguez-Galindo, D.Bernstein, C.Delbrook, M.Lodish, R.Bishop, J.D.Wolchok, et al. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin Cancer Res 2016; 22:1364-70; PMID:26534966; http://dx.doi.org/10.1158/1078-0432.CCR-15-0491
74. S.Tarp, G.Amarilyo, I.Foeldvari, R.Christensen, J.M.Woo, N.Cohen, T.D.Pope, D.E.Furst. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis:a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford, England) 2016; 55:669-79; PMID:26628580; http://dx.doi.org/10.1093/rheumatology/kev382
75. S.Yokota, Y.Itoh, T.Morio, H.Origasa, N.Sumitomo, M.Tomobe, K.Tanaka, S.Minota. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting:results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 2015; PMID:26644233